36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
